GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OmniAb OABI · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.66

-7.36%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

OmniAb — daily OABI Delayed
Market value
$529.5m
Last close × shares
Volume
1.9m
Shares, 20 Nov 2026

About OmniAb

From its filings with the US Securities and Exchange Commission

SEC filings

OmniAb is based in Emeryville, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker OABI. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $18.7m and a net loss of $64.8m. At that date it held total assets of $300.9m and shareholders' equity of $267.0m.

In its own words

OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological IntelligenceTM, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns our interests with the scientific and economic interests of our partners through structured platform license agreements that generally include upfront or annual access fees, service revenue, milestones and royalties on commercial sales.

Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗

More about OmniAb →

Latest on OmniAb

Our reporting

Next results

3 Mar 2027

Due on 3 Mar 2027. Analysts expect earnings of -0.12 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is OmniAb's ticker?

OmniAb trades as OABI on its US listing, under ISIN US68218J1034.

What was OmniAb's last closing price?

4.66 on 20 Nov 2026. The figure is in USD and is never converted.

When does OmniAb next report results?

Results are expected on 3 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.